Summit Therapeutics Inc. (SMMT)
| Bid | 18.03 |
| Market Cap | 13.43B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -746.08M |
| EPS (ttm) | -1.01 |
| PE Ratio (ttm) | -17.91 |
| Forward PE | -29.14 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 18.15 |
| Volume | 3,868,301 |
| Avg. Volume (20D) | 3,888,903 |
| Open | 17.76 |
| Previous Close | 18.12 |
| Day's Range | 17.76 - 18.54 |
| 52-Week Range | 15.55 - 36.91 |
| Beta | -1.03 |
| Ex-Dividend Date | n/a |
About SMMT
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for SMMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAnalysts project revenue of ... Unlock content with Pro Subscription
1 week ago · proactiveinvestors.com
Summit Therapeutics shares fall as lung cancer trial results disappointSummit Therapeutics PLC (NASDAQ:SMMT) shares dropped sharply on Monday following the release of mixed results from its Phase III HARMONi trial of ivonescimab, a potential lung cancer therapy. The stoc...
3 weeks ago · https://thefly.com
Summit Therapeutics price target raised to $50 from $44 at H.C. WainwrightH.C. Wainwright raised the firm's price target on Summit Therapeutics to $50 from $44 and keeps a Buy rating on the shares. The firm believes Akeso's HARMONi-A study for ivonescimab validates the Chin...
4 weeks ago · https://thefly.com
Piper starts Summit Therapeutics with Neutral on high expectationsPiper Sandler analyst Kelsey Goodwin last night initiated coverage of Summit Therapeutics with a Neutral rating and $21 price target. The firm believes investor expectations for ivonescimab are too hi...
